Investor Northpond Ventures, LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Northpond Ventures, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-06-11 13G MREO / Mereo BioPharma Group plc - Depositary Receipt (Common Stock) 54,521,000
2025-05-27 13D/A VIGL / Vigil Neuroscience, Inc. 4,214,498 0
2025-02-14 13G/A CADL / Candel Therapeutics, Inc. 1,935,215 0
2024-11-06 13D/A 1,039,577
2024-07-18 13D/A 1,034,546
2024-06-10 13D/A TBIO / Telesis Bio, Inc. 18,306,873 1,032,874
2023-06-23 13D/A DICE / DICE Therapeutics Inc 3,292,871 800,000
2023-06-15 13D/A ISO / IsoPlexis Corp 8,808,531 0
2023-06-07 13D/A TBIO / Telesis Bio, Inc. 9,844,130 18,306,873
2023-04-19 13D/A TBIO / Telesis Bio, Inc. 9,844,130 9,844,130
2023-03-29 13G BLI / Berkeley Lights Inc 5,390,820
2022-12-22 13D/A ISO / IsoPlexis Corp 8,808,531 8,808,531
2022-12-16 13D/A VIGL / Vigil Neuroscience, Inc. 4,214,498 4,214,498
2022-11-10 13D/A DICE / DICE Therapeutics Inc 3,292,871 3,292,871
2022-02-14 13G CADL / Candel Therapeutics, Inc. 1,935,215
2022-01-19 13D VIGL / Vigil Neuroscience, Inc. 4,214,498
2021-10-22 13D ISO / IsoPlexis Corp 8,808,531
2021-09-28 13D DICE / DICE Therapeutics Inc 3,292,871
2021-07-01 13D DNAY / Codex DNA Inc 9,844,130